[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4005 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 4005

  To direct the Comptroller General of the United States to conduct a 
                       study on naloxone access.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             June 12, 2023

Ms. Kuster (for herself, Ms. Blunt Rochester, and Ms. Craig) introduced 
 the following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
  To direct the Comptroller General of the United States to conduct a 
                       study on naloxone access.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Naloxone Affordability Act of 
2023''.

SEC. 2. STUDY ON NALOXONE ACCESS.

    (a) In General.--The Comptroller General of the United States shall 
conduct a study on actions that may be taken to ensure appropriate 
access and affordability of naloxone for individuals seeking to 
purchase naloxone. Such study shall address what is known about--
            (1) coverage of naloxone (in any available form), including 
        whether naloxone can be covered as an over-the-counter drug 
        under a group health plan or group or individual health 
        insurance coverage (as such terms are defined in section 2791 
        of the Public Health Service Act (42 U.S.C. 300gg-91)) or for 
        individuals entitled to benefits under part A or enrolled under 
        part B of title XVIII of the Social Security Act (42 U.S.C. 
        1395 et seq.) or receiving medical assistance under a State 
        plan under title XIX of such Act (42 U.S.C. 1396 et seq.) or a 
        waiver of such plan;
            (2) the out-of-pocket cost to consumers purchasing 
        naloxone--
                    (A) with a prescription, with and without coverage 
                under any such plan or coverage;
                    (B) over the counter, with and without coverage 
                under any such plan or coverage; and
                    (C) pursuant to a standing order; and
            (3) other factors impacting coverage, including barriers in 
        covering naloxone as an over-the-counter drug, the relative net 
        costs of naloxone when purchased over the counter without 
        insurance coverage compared to when purchased with a 
        prescription and covered under a group health plan or health 
        insurance coverage, and the availability of naloxone purchased 
        and distributed through public health entities.
    (b) Report.--Not later than 2 years after the date of the enactment 
of this Act, the Comptroller General of the United States shall submit 
to Congress a report that contains the findings of the study conducted 
under subsection (a).
                                 <all>